French industry: Mediator crisis a one-off, not a symptom
This article was originally published in Scrip
Executive Summary
The French pharmaceutical establishment is portraying the scandal surrounding Servier’s diabetes drug, Mediator, as an isolated case: one drug, one company, one regulatory deficiency. Time, and ongoing inquiries, may confirm this. But there are also suspicions that this affair is only one manifestation of a systemic failure. Could there be other Mediators out there?